LBT Innovations Limited

LBTN

LBT Innovations Ltd. is an Australian developer of clinical and diagnostic technology, which has emerged as a groundbreaking designer of advanced automated solutions for the preparation and analysis of microbiology culture specimens, with significant benefits for busy clinical laboratories. The company is headquartered in Adelaide, South Australia and currently employs 17 full-time employees. The company went IPO on 2006-07-31. Its principal activities includes researching, developing, and commercializing technologies for the healthcare and laboratory supply markets. Its capabilities include artificial intelligence (AI), image analysis and software engineering solutions that improve medical diagnostic workflows. Its Automated Plate Assessment System (APAS) is a platform technology that automates culture-plate screening and interpretation. Its products include APAS Independence and APAS Analysis Modules. The APAS Independence combines AI, software and imaging analysis to create a platform technology for intelligent image interpretation. The APAS Analysis Modules are the intelligent image analysis software that works together with the APAS Independence to enable the screening of microbiology culture plates. Its pipeline includes APAS- antimicrobial resistance (AMR) Analysis Module, Automated Gram Stain Assessment, Biofilm, MicroStreak and WoundVue.

LBT Innovations Limited

LBT

LBT Innovations Ltd. engages in the business of researching, developing, and commercializing innovative technologies for healthcare and laboratory supply markets. The company is headquartered in Adelaide, South Australia. The company went IPO on 2006-07-31. The firm has developed a technology, the Automated Plate Assessment System (APAS Independence), using artificial intelligence and machine learning software to automate the imaging, analysis and interpretation of microbiology culture plates. The technology remains the only US FDA-cleared artificial intelligence technology for automated culture plate reading and is being commercialized through LBT’s wholly owned subsidiary Clever Culture Systems AG (CCS). The product is being sold to microbiology laboratories in the pharmaceutical manufacturing sector for the reading of environmental monitoring culture plates and to clinical laboratories as an in vitro diagnostic for infectious diseases. Thermo Fisher Scientific, Inc is exclusive distributor of the APAS Independence to clinical customers in the United States and selected countries in Europe.